SCHEMBL1173259

SCHEMBL1173259

CC(C)c1cccc(/C=C/C(=O)O)c1C(C)C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.66
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
NFKB1 P19838 1/20 0.47
CA4 P22748 1/20 0.47
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.41
MAPT P10636 1/20 0.41
PARP1 P09874 1/20 0.41
HDAC3 O15379 1/20 0.40
TNKS O95271 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL819054 0.84 CA1 (0.56) KDM4ECA1CA2NFKB1CA4
SCHEMBL28414685 0.84 CA1 (0.56) KDM4ECA1CA2NFKB1CA4
SCHEMBL8218747 0.83 KDM4E (0.66) KDM4ECA1CA2NFKB1CA4
SCHEMBL579354 0.83 KDM4E (0.54) KDM4ECA1CA2HTTMAPT
2-Isopropyl-3-Methoxycinnamic Acid SCHEMBL2280935 0.80 KDM4E (1.00) KDM4ECA1CA2CA4MAPK1
2-Isopropyl-3-Methoxycinnamic Acid SCHEMBL2280937 0.80 KDM4E (1.00) KDM4ECA1CA2CA4MAPK1
SCHEMBL15512 0.79 KDM4E (0.47) KDM4ECA1CA2MAPK1MAPT
SCHEMBL2480692 0.79 KDM4E (0.49) KDM4ECA1CA2NFKB1CA4
SCHEMBL489850 0.79 KDM4E (0.52) KDM4ECA1CA2NFKB1CA4
SCHEMBL8575018 0.76 CA1 (0.55) KDM4ECA1CA2NFKB1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2874507-B1 AQUEOUS TRANSPARENT OIL-IN-WATER EMULSION COMPRISING AN EMULSIFIED CAROTENOID BASF SE (DE) 2020-12-30 EP claimed
EP-3307395-B1 SOLUBILISING AGENTS FOR UV SCREENING COMPOUNDS ISP INVESTMENTS LLC (US) 2020-08-05 EP claimed
EP-2485807-B1 SUN-CARE COMPOSITIONS ISP INVESTMENTS LLC (US) 2019-07-03 EP claimed
EP-2687103-B1 Process for manufacturing an aqueous transparent oil-in-water emulsion comprising a carotenoid and emulsion produced BASF SE (DE) 2019-05-22 EP claimed
EP-1595936-B1 COMPOSITION FOR EXTERNAL USE VITAMIN C60 BIORES CORP (JP) 2011-10-19 EP claimed
US-12605315-B2 External skin preparation KAO CORPORATION (JP) 2026-04-21 US disclosed
US-12551424-B2 Oil-in-water type emulsification composition containing UV wavelength conversion substance SHISEIDO COMPANY, LTD. (JP) 2026-02-17 US disclosed
US-12440431-B2 Cosmetic comprising ultraviolet wavelength conversion substance SHISEIDO COMPANY, LTD. (JP) 2025-10-14 US disclosed
US-12419818-B2 External preparation KAO CORPORATION (JP) 2025-09-23 US disclosed
US-12409118-B2 External skin preparation KAO CORPORATION (JP) 2025-09-09 US disclosed
US-20250255791-A1 POWDER COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH-CONVERTING SUBSTANCE, AND METHOD FOR PRODUCING SAME SHISEIDO COMPANY, LTD. (JP) 2025-08-14 US disclosed
US-20250152484-A1 OIL-IN-WATER EMULSION SKIN PREPARATION FOR EXTERNAL USE KAO CORPORATION (JP) 2025-05-15 US disclosed
EP-1256336-A2 Two-phase gel composition Penreco (US) 2002-11-13 EP disclosed
EP-1235552-A2 MATERIAL COMPRISING AN ORGANIC UV-A FILTER AND METHOD FOR DISPLACING THE MAXIMUM ABSORPTION WAVELENGTH L'OREAL (FR) 2002-09-04 EP disclosed
WO-2002055034-A2 COSMETIC COMPOSITIONS CONTAINING A FRUCTAN, A POLYSACCHARIDE AND A BENEFICIAL AGENT, AND USES THEREOF L'OREAL (FR) 2002-07-18 WO disclosed
US-20020055562-A1 Gel compositions WILMINGTON TRUST, NATIONAL ASSOCIATION 2002-05-09 US disclosed
WO-2002007699-A1 USE AND COSMETIC COMPOSITIONS OF STARCH BETAINATES L'OREAL (FR) 2002-01-31 WO disclosed
EP-1141111-A1 GEL COMPOSITIONS Penreco (US) 2001-10-10 EP disclosed
WO-2001024768-A2 MATERIAL COMPRISING AN ORGANIC UV-A FILTER AND METHOD FOR DISPLACING THE MAXIMUM ABSORPTION WAVELENGTH L'OREAL (FR) 2001-04-12 WO disclosed
WO-2000026285-A1 GEL COMPOSITIONS PENRECO (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605315-B2 External skin preparation TLR5, CUTA, TLR3 KDM4E 1765/4885CA1 3580/4885CA2 3273/4885
US-12409118-B2 External skin preparation CUTA, RBP4, DSG1 KDM4E 1990/4885CA1 4804/4885CA2 4788/4885
US-12551424-B2 Oil-in-water type emulsification composition containing UV wavelength conversion substance PCNA, CD14, TP53 KDM4E 1150/4885CA1 4508/4885CA2 3453/4885
US-20250152484-A1 OIL-IN-WATER EMULSION SKIN PREPARATION FOR EXTERNAL USE CUTA, NAPEPLD, LIPA KDM4E 4099/4885CA1 4115/4885CA2 3724/4885
US-12419818-B2 External preparation CUTA, ALOX15, HSF1 KDM4E 3201/4885CA1 4501/4885CA2 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.